Targeting BET bromodomains for cancer treatment

The bromodomain and extraterminal (BET) subfamily of bromodomain-containing proteins has emerged in the last few years as an exciting, novel target group. BRD4, the best studied BET protein, is implicated in a number of hematological and solid tumors. This is linked to its role in modulating transcr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Epigenomics 2015-06, Vol.7 (3), p.487-501
Hauptverfasser:	Jung, Marie, Gelato, Kathy A, Fernández-Montalván, Amaury, Siegel, Stephan, Haendler, Bernard
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino acids Analysis Animals Anticancer properties Antineoplastic Agents - therapeutic use Antitumor activity Apoptosis BET inhibitor Bet protein Binding sites BRD4 bromodomain c-Myc c-Myc protein Cancer Cancer therapies Care and treatment Cell cycle chromatin Cyclin-dependent kinases Development and progression Elongation Genes Genetic transcription Genomes Health aspects Hematologic Neoplasms - drug therapy Humans Inhibitors Kinases Ligands Lymphoma Mice Myc protein Nuclear Proteins - antagonists & inhibitors Nuclear Proteins - chemistry Nuclear Proteins - metabolism Nuclear Proteins - physiology Physiology Protein Structure, Tertiary Protein-protein interactions Proteins Solid tumors T cell lymphoma transcription control Transcription elongation Transcription Factors - antagonists & inhibitors Transcription Factors - chemistry Transcription Factors - metabolism Transcription Factors - physiology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!